Exclusion of biglycan mutations in a cohort of patients with neuromuscular disorders

Neuromuscular Disorders

Volumn 18, Issue 8, 2008, Pages 606-609

  Peat, Rachel A ^a   Gécz, Jozef ^b,c   Fallon, Justin R ^d   Tarpey, Patrick S ^e   Smith, Raffaella ^e   Futreal, Andrew ^e   Stratton, Michael R ^e   Lamandé, Shireen R ^f,g   Yang, Nan ^a   North, Kathryn N ^a,h  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d BROWN UNIVERSITY   (United States)

^e WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^f MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Dystroglycan; Biglycan; Collagen VI; Congenital muscular dystrophy

Indexed keywords

BIGLYCAN;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCULAR DYSTROPHY; NEUROMUSCULAR DISEASE; PRIORITY JOURNAL;

ADULT; COHORT STUDIES; COLLAGEN TYPE VI; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENES, X-LINKED; HUMANS; MALE; MUTATION; MYOTONIC DYSTROPHY; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEOGLYCANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VARIATION (GENETICS);

EID: 48549092255     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2008.05.013     Document Type: Article

References (23)

1. Peat R.A., Smith J.M., Compton A.G., et al. The diagnosis and etiology of congenital muscular dystrophy. Neurology (2007) (Epub ahead of print)
2. Lo H.P., Cooper S.T., Evesson F.J., et al. Limb-girdle muscular dystrophy: diagnostic evaluation, frequency and clues to pathogenesis. Neuromuscul Disord (2007)
3. Hocking A.M., Shinomura T., and McQuillan D.J. Leucine-rich repeat glycoproteins of the extracellular matrix. Matrix Biol 17 (1998) 1-19
4. Ameye L., Aria D., Jepsen K., et al. Abnormal collagen fibrils in tendons of biglycan/fibromodulin-deficient mice lead to gait impairment, ectopic ossification, and osteoarthritis. FASEB J 16 (2002) 673-680
5. Bianco P., Fisher L.W., Young M.F., Termine J.D., and Robey P.G. Expression and localization of the two small proteoglycans biglycan and decorin in developing human skeletal and non-skeletal tissues. J Histochem Cytochem 38 (1990) 1549-1563
6. Bowe M.A., Mendis D.B., and Fallon J.R. The small leucine-rich repeat proteoglycan biglycan binds to alpha-dystroglycan and is upregulated in dystrophic muscle. J Cell Biol 148 (2000) 801-810
7. Rafii M.S., Hagiwara H., Mercado M.L., et al. Biglycan binds to alpha- and gamma-sarcoglycan and regulates their expression during development. J Cell Physiol 209 (2006) 439-447
8. Wiberg C., Heinegard D., Wenglen C., Timpl R., and Morgelin M. Biglycan organizes collagen VI into hexagonal-like networks resembling tissue structures. J Biol Chem 277 (2002) 49120-49126
9. Neuromuscular disorders: gene location. Neuromuscul Disord 2006;16:64-90.
10. Young M.F., Bi Y., Ameye L., and Chen X.D. Biglycan knockout mice: new models for musculoskeletal diseases. Glycoconj J 19 (2002) 257-262
11. Corsi A., Xu T., Chen X.D., et al. Phenotypic effects of biglycan deficiency are linked to collagen fibril abnormalities, are synergized by decorin deficiency, and mimic Ehlers-Danlos-like changes in bone and other connective tissues. J Bone Miner Res 17 (2002) 1180-1189
12. Wiberg C., Klatt A.R., Wagener R., et al. Complexes of matrilin-1 and biglycan or decorin connect collagen VI microfibrils to both collagen II and aggrecan. J Biol Chem 278 (2003) 37698-37704
13. Xu T., Bianco P., Fisher L.W., et al. Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nat Genet 20 (1998) 78-82
14. Ameye L., and Young M.F. Mice deficient in small leucine-rich proteoglycans: novel in vivo models for osteoporosis, osteoarthritis, Ehlers-Danlos syndrome, muscular dystrophy, and corneal diseases. Glycobiology 12 (2002) 107R-116R
15. Mercado M.L., Amenta A.R., Hagiwara H., et al. Biglycan regulates the expression and sarcolemmal localization of dystrobrevin, syntrophin, and nNOS. FASEB J 20 (2006) 1724-1726
16. Jones K.J., Compton A.G., Yang N., et al. Deficiency of the syntrophins and alpha-dystrobrevin in patients with inherited myopathy. Neuromuscul Disord 13 (2003) 456-467
17. Tarpey P.S., Raymond F.L., Nguyen L.S., et al. Mutations in UPF3B, a member of the nonsense-mediated mRNA decay complex, cause syndromic and nonsyndromic mental retardation. Nat Genet 39 (2007) 1127-1133
18. Ishikawa H., Sugie K., Murayama K., et al. Ullrich disease due to deficiency of collagen VI in the sarcolemma. Neurology 62 (2004) 620-623
19. Fadic R., Mezzano V., Alvarez K., et al. Increase in decorin and biglycan in Duchenne Muscular Dystrophy: role of fibroblasts as cell source of these proteoglycans in the disease. J Cell Mol Med 10 (2006) 758-769
20. Zanotti S., Negri T., Cappelletti C., et al. Decorin and biglycan expression is differentially altered in several muscular dystrophies. Brain 128 (2005) 2546-2555
21. Hayashi Y.K., Chou F.L., Engvall E., et al. Mutations in the integrin alpha7 gene cause congenital myopathy. Nat Genet 19 (1998) 94-97
22. Pegoraro E., Cepollaro F., Prandini P., et al. Integrin alpha 7 beta 1 in muscular dystrophy/myopathy of unknown etiology. Am J Pathol 160 (2002) 2135-2143
23. Lechner B.E., Lim J.H., Mercado M.L., and Fallon J.R. Developmental regulation of biglycan expression in muscle and tendon. Muscle Nerve (2006)